ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tipiracil

Its studies are mostly in Colorectal Neoplasms, led by Simcere Pharmaceutical Group.

Drug pageTipiracil: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 30, 20251 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group11 open or runningphase 3since Sep 30, 2025Sep 30, 2025Jan 2028phase 3 · NCT07361003

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 30, 2025First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT07361003 · 464 planned · China

Ahead

  1. Jan 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07361003

TargetBeta

TYMP →read by rule
“Thymidine phosphorylase inhibitor”ChEMBL 37, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07361003Colorectal Neoplasms · China3RecruitingJan 2028464

How it is read

Names in the registry

  • “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.